Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 15Leiomyoma 4Myofibroma 2Endometriosis 2Uterine Neoplasms 1Uterine Hemorrhage 1Prostate Adenocarcinoma 1Pregnancy Complications 1Pathologic Complete Response 1Neoplasm, Residual 1Neoplasm Metastasis 1Myoma 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Menorrhagia 1Adenocarcinoma 1

Interventions

relugolix 2Uterine Myomectomy 1Transcranial Direct Current Stimulation 1Sutures 1Radiotherapy 1Radiation 1Immunonutrition Diet 1Hysteroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Endometriosis × relugolix × Clear all
NCT05739123 2025-08-19

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Sumitomo Pharma Switzerland GmbH

Recruiting
728 enrolled

Endometriosis, Leiomyoma, Pregnancy Complications

NCT05862272 2025-08-06

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Sumitomo Pharma Switzerland GmbH

Phase 3 Recruiting
1,000 enrolled

Endometriosis, Leiomyoma, Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡